Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Immediate-Release Viloxazine in Adults with ADHD
NCT01107496Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Jun 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing IR Viloxazine with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events During 6 Weeks of Treatment. Started Jun 2010; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01107496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107496.